Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment

Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment

A comprehensive analysis was done to evaluate the potential use of anti-parasitic macrocyclic lactones (including avermectins and milbemycins) for Buruli ulcer (BU) therapy. A panel containing nearly all macrocyclic lactones used in human or in veterinary medicine was analyzed for activity in vitro against clinical isolates of Mycobacterium ulcerans. Milbemycin oxime and selamectin were the mos...

Buruli ulcer.

Buruli ulcer, an infectious disease caused by Mycobacterium ulcerans, is the third most prevalent mycobacteriosis, after tuberculosis and leprosy. This atypical mycobacteriosis has been reported in over 30 countries, mainly those with tropical and subtropical climates, but its epidemiology remains unclear. The first autochthonous cases of infection in Brazil have recently been described, making...

Compliance with antimicrobial therapy for buruli ulcer.

A Theoretical Model for the Transmission Dynamics of the Buruli Ulcer with Saturated Treatment

The management of the Buruli ulcer (BU) in Africa is often accompanied by limited resources, delays in treatment, and macilent capacity in medical facilities. These challenges limit the number of infected individuals that access medical facilities. While most of the mathematical models with treatment assume a treatment function proportional to the number of infected individuals, in settings wit...

Treatment Outcome of Patients with Buruli Ulcer Disease in Togo

BACKGROUND Following introduction of antimycobacterial treatment of Buruli ulcer disease (BUD), several clinical studies evaluated treatment outcomes of BUD patients, in particular healing times, secondary lesions and functional limitations. Whereas recurrences were rarely observed, paradoxical reactions and functional limitations frequently occurred. Although systematic BUD control in Togo was...